摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-chlorophenyl)-5-(3-phenyl-1H-pyrazol-4-yl)-1,2,4-oxadiazole

中文名称
——
中文别名
——
英文名称
3-(4-chlorophenyl)-5-(3-phenyl-1H-pyrazol-4-yl)-1,2,4-oxadiazole
英文别名
3-(4-chlorophenyl)-5-(5-phenyl-1H-pyrazol-4-yl)-1,2,4-oxadiazole
3-(4-chlorophenyl)-5-(3-phenyl-1H-pyrazol-4-yl)-1,2,4-oxadiazole化学式
CAS
——
化学式
C17H11ClN4O
mdl
——
分子量
322.7
InChiKey
AOAQSUXMHOBCDJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    67.6
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • GLUCOKINASE ACTIVATORS
    申请人:Cao X. Sheldon
    公开号:US20070197532A1
    公开(公告)日:2007-08-23
    Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
    提供了用于与葡萄糖激酶一起使用的化合物、药物组合物、试剂盒和方法,其中包括从以下组中选择的化合物:其中变量如本文所定义。
  • CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES
    申请人:Electrophoretics Limited
    公开号:US20160354375A1
    公开(公告)日:2016-12-08
    The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
  • ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE
    申请人:Magenta Therapeutics Inc.
    公开号:US20210220408A1
    公开(公告)日:2021-07-22
    The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies, such as cancer, by administration of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. The disclosure further relates to pharmaceutical compositions comprising the compounds and methods of treating or preventing a disease in which aryl hydrocarbon receptor plays a role.
  • [EN] GLUCOKINASE ACTIVATORS<br/>[FR] ACTIVATEURS DE LA GLUCOKINASE
    申请人:TAKEDA SAN DIEGO INC
    公开号:WO2007061923A2
    公开(公告)日:2007-05-31
    [EN] Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula [I] wherein the variables are as defined herein.
    [FR] L'invention porte sur des composés des préparations pharmaceutiques des trousses et des méthodes s'utilisant avec la glucokinase et comportant un composé sélectionné dans le groupe de formule (I) dont les variables sont définies dans la description.
查看更多